𩺠å
§ç§å°ç§èåç
1ïžâ£ Shingrix in Immunocompromise (Ch 198 update)
- 2021 ACIP expansion: ⥠19 yr immunocompromise
- Includes HSCT, SOT, hematologic malignancy, HIV (any CD4)
- 2 doses 1-2 mo apart (faster than general 50+)
- Efficacy lower (~ 70%) but still beneficial
- Pre-transplant vaccination encouraged
2ïžâ£ PHN Prevention
- Early antiviral (< 72 hr) reduces PHN risk slightly
- Vaccination = best prevention
- Steroid: doesnât reduce PHN
- Gabapentinoid early treatment + may reduce PHN slightly (mixed)
- Acupuncture, capsaicin some evidence
3ïžâ£ Herpes Zoster Ophthalmicus Management
- Emergent ophthalmology consult
- IV acyclovir 10 mg/kg q8h à 7-14d
- Topical antiviral (trifluridine, ganciclovir gel)
- Steroid eye drops only under ophthalmology
- Pain management
- Monitor for: keratitis, uveitis, retinitis (acute retinal necrosis), VI palsy
- Long follow-up (sequelae possible)
4ïžâ£ Ramsay Hunt Syndrome
- Geniculate ganglion VZV reactivation
- VII (facial) + VIII (auditory) involvement
- Facial palsy + ear vesicles + vertigo + hearing loss + tinnitus
- Higher residual paralysis vs Bellâs palsy
- Treatment: acyclovir IV + steroid
- ENT + neurology consult
5ïžâ£ Acute Retinal Necrosis (ARN)
- VZV (or HSV) retinitis
- Rapidly progressive retinal necrosis + vasculitis
- Visual loss, retinal detachment
- IV acyclovir à 14d â PO valacyclovir à 4-6 wk
- Intravitreal foscarnet adjunct
- Vitrectomy for retinal detachment
6ïžâ£ VZV Encephalitis / Vasculopathy
- Large + small vessel vasculopathy
- Ischemic + hemorrhagic stroke in zoster patients (especially elderly)
- CSF VZV PCR positive
- MRI brain: vasculitis, infarcts
- Acyclovir IV Ã 14-21d
- Antiplatelet / anticoagulation per stroke management
7ïžâ£ å¥ä¿ / Taiwan
- å
¬è²» Varivax childhood routine
- Shingrix èªè²» (about NT$5,000-7,000 per dose, 2 doses)
- å¥ä¿ acyclovir / valacyclovir for confirmed zoster
- IV acyclovir admit indication
- ç§é«åž« hint: ç³å°¿ç
/ æ
¢ç
/ è 50+ äžå®èŠ push Shingrix èªè²» vaccine â PHN å° quality of life å€ªç Žå£
8ïžâ£ Vaccine Hesitancy + Counseling
- Common reasons: cost, âIâm healthyâ, âI had chickenpox so Iâm immuneâ
- Counter:
- Cost vs cost of zoster + PHN
- Reactivation risk regardless of past varicella history (in fact requires past varicella)
- PHN devastating impact
- Shared decision-making
9ïžâ£ Future
- mRNA zoster vaccines in development
- New antivirals (helicase-primase inhibitor, novel mechanism)
- Anti-PHN strategies (botulinum toxin trials)